Doxycycline hyclate delayed-release - Allergan

Drug Profile

Doxycycline hyclate delayed-release - Allergan

Alternative Names: Doryx; WC 2055; WC-2031

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Warner Chilcott
  • Developer Allergan
  • Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris; Chlamydial infections

Most Recent Events

  • 23 May 2016 First Generic equivalent available in USA for Acne vulgaris
  • 09 Feb 2015 Doxycycline hyclate delayed-release to be divested to Mayne Pharma in USA
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top